AR111288A1 - Anticuerpos anti-phf-tau y sus usos - Google Patents
Anticuerpos anti-phf-tau y sus usosInfo
- Publication number
- AR111288A1 AR111288A1 ARP180100620A ARP180100620A AR111288A1 AR 111288 A1 AR111288 A1 AR 111288A1 AR P180100620 A ARP180100620 A AR P180100620A AR P180100620 A ARP180100620 A AR P180100620A AR 111288 A1 AR111288 A1 AR 111288A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- phf
- tau antibodies
- tau
- tauopathies
- Prior art date
Links
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se describen anticuerpos anti-PHF-tau monoclonales y fragmentos de unión al antígeno de estos. También se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y el uso de los anticuerpos para tratar o prevenir afecciones tales como tauopatías.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472214P | 2017-03-16 | 2017-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111288A1 true AR111288A1 (es) | 2019-06-26 |
Family
ID=63521020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100620A AR111288A1 (es) | 2017-03-16 | 2018-03-16 | Anticuerpos anti-phf-tau y sus usos |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10766953B2 (es) |
| EP (1) | EP3596119A4 (es) |
| JP (3) | JP7159185B2 (es) |
| KR (2) | KR102597462B1 (es) |
| CN (2) | CN117209599A (es) |
| AR (1) | AR111288A1 (es) |
| AU (1) | AU2018234709B2 (es) |
| CA (1) | CA3055598A1 (es) |
| CL (1) | CL2019002566A1 (es) |
| EA (1) | EA201992038A1 (es) |
| IL (2) | IL268700B2 (es) |
| JO (1) | JOP20180021A1 (es) |
| MA (1) | MA47789A (es) |
| MX (1) | MX2019010922A (es) |
| PH (1) | PH12019501973A1 (es) |
| SG (1) | SG11201907754RA (es) |
| TW (1) | TWI771389B (es) |
| UA (1) | UA128385C2 (es) |
| UY (1) | UY37635A (es) |
| WO (1) | WO2018170351A1 (es) |
| ZA (1) | ZA202101318B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| EP3452508A1 (en) | 2016-05-02 | 2019-03-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
| JP7170316B2 (ja) | 2016-05-02 | 2022-11-14 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
| BR112019017021A2 (pt) | 2017-02-17 | 2020-04-14 | Denali Therapeutics Inc | anticorpos anti-tau e métodos de uso dos mesmos |
| CA3061516A1 (en) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
| AU2018352308A1 (en) | 2017-10-16 | 2020-03-19 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| US10633435B2 (en) | 2018-03-05 | 2020-04-28 | Janssen Pharmaceutica Nv | Anti-PHF-tau antibodies and uses thereof |
| BR112021016947A2 (pt) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Anticorpos que reconhecem tau |
| EP3977135A1 (en) * | 2019-05-31 | 2022-04-06 | Eli Lilly And Company | Compounds and methods targeting human tau |
| KR102509648B1 (ko) * | 2019-08-06 | 2023-03-15 | 아프리노이아 테라퓨틱스 리미티드 | 병리학적 타우 종에 결합하는 항체 및 이의 용도 |
| PE20230385A1 (es) * | 2020-04-08 | 2023-03-06 | Janssen Biotech Inc | Anticuerpos anti-phf-tau y usos de estos |
| JP2023533806A (ja) * | 2020-07-14 | 2023-08-04 | ヤンセン ファーマシューティカ エヌ．ベー． | タウオパチー又はアミロイド形成疾患を検出するための血液ベースのアッセイ |
| IL302383A (en) * | 2020-10-26 | 2023-06-01 | Janssen Pharmaceutica Nv | Method of safe administration of anti-tau antibody |
| KR20230093499A (ko) * | 2020-10-26 | 2023-06-27 | 얀센 파마슈티카 엔.브이. | 인간 대상체에서 타우를 감소시키는 방법 |
| CA3203800A1 (en) * | 2021-02-19 | 2022-08-25 | Eisai R&D Management Co., Ltd. | Anti-pt217 tau antibody |
| AU2022242135A1 (en) | 2021-03-26 | 2023-11-09 | Janssen Biotech, Inc. | Anti-tau antibodies and uses thereof |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN117003863A (zh) * | 2022-04-28 | 2023-11-07 | 厦门大学 | 针对p-tau 217的抗体及其用途 |
| CN116948024B (zh) * | 2023-09-14 | 2024-02-06 | 北京凯祥弘康生物科技有限公司 | 抗Tau蛋白的捕获抗体 |
| CN116948023B (zh) * | 2023-09-14 | 2024-02-09 | 北京凯祥弘康生物科技有限公司 | Tau蛋白抗体及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
| AU662178B2 (en) | 1991-10-25 | 1995-08-24 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau |
| DE69434811T2 (de) * | 1993-12-21 | 2007-03-01 | Innogenetics N.V. | Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen |
| AU710952B2 (en) | 1994-07-29 | 1999-09-30 | Innogenetics N.V. | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| US7657380B2 (en) | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
| EP1590369B1 (en) | 2003-01-24 | 2016-03-16 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| WO2005079479A2 (en) | 2004-02-17 | 2005-09-01 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP2420252A1 (en) | 2006-08-04 | 2012-02-22 | Novartis AG | EPHB3-specific antibody and uses thereof |
| JP2010235447A (ja) | 2007-07-30 | 2010-10-21 | Igaku Seibutsugaku Kenkyusho:Kk | 炎症性サイトカインの抑制剤 |
| US20100261620A1 (en) | 2008-10-14 | 2010-10-14 | Juan Carlos Almagro | Methods of Humanizing and Affinity-Maturing Antibodies |
| CA2742968C (en) | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| US9968574B2 (en) | 2009-05-15 | 2018-05-15 | The University Of Kentucky Research Foundation | Treatment of MCI and Alzheimer's disease |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| CA2765099A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Phosphorylated tau peptide for use in the treatment of tauopathy |
| US8912355B2 (en) | 2009-09-29 | 2014-12-16 | University Of Ottawa Heart Institute | Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes |
| DK2488867T3 (da) | 2009-10-14 | 2020-11-09 | Janssen Biotech Inc | Fremgangsmåder til affinitetsmodning af antistoffer |
| RU2568051C2 (ru) * | 2010-04-09 | 2015-11-10 | Авео Фармасьютикалз, Инк. | АНТИТЕЛА К ErbB3 |
| JP6371526B2 (ja) | 2010-10-07 | 2018-08-08 | エーシー イミューン エス．エー． | タウを認識するリン酸化部位特異的抗体 |
| BR112013008765B8 (pt) | 2010-10-11 | 2023-05-02 | Biogen Idec Int Neuroscience Gmbh | Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa |
| SMT201900421T1 (it) | 2011-12-20 | 2019-09-09 | Janssen Biotech Inc | Anticorpi anti-phf-tau e loro usi |
-
2017
- 2017-03-16 JO JOP/2018/0021A patent/JOP20180021A1/ar unknown
-
2018
- 2018-03-15 TW TW107108890A patent/TWI771389B/zh active
- 2018-03-16 US US15/923,011 patent/US10766953B2/en active Active
- 2018-03-16 EP EP18767083.1A patent/EP3596119A4/en active Pending
- 2018-03-16 MA MA047789A patent/MA47789A/fr unknown
- 2018-03-16 WO PCT/US2018/022782 patent/WO2018170351A1/en active Application Filing
- 2018-03-16 AR ARP180100620A patent/AR111288A1/es unknown
- 2018-03-16 UA UAA201910307A patent/UA128385C2/uk unknown
- 2018-03-16 MX MX2019010922A patent/MX2019010922A/es unknown
- 2018-03-16 CA CA3055598A patent/CA3055598A1/en active Pending
- 2018-03-16 CN CN202310854848.XA patent/CN117209599A/zh active Pending
- 2018-03-16 AU AU2018234709A patent/AU2018234709B2/en active Active
- 2018-03-16 IL IL268700A patent/IL268700B2/en unknown
- 2018-03-16 KR KR1020197028728A patent/KR102597462B1/ko active IP Right Grant
- 2018-03-16 IL IL310464A patent/IL310464A/en unknown
- 2018-03-16 SG SG11201907754RA patent/SG11201907754RA/en unknown
- 2018-03-16 KR KR1020237037321A patent/KR102695287B1/ko active IP Right Grant
- 2018-03-16 EA EA201992038A patent/EA201992038A1/ru unknown
- 2018-03-16 JP JP2019549574A patent/JP7159185B2/ja active Active
- 2018-03-16 UY UY0001037635A patent/UY37635A/es unknown
- 2018-03-16 CN CN201880018431.7A patent/CN110799531B/zh active Active
-
2019
- 2019-08-28 PH PH12019501973A patent/PH12019501973A1/en unknown
- 2019-09-09 CL CL2019002566A patent/CL2019002566A1/es unknown
-
2020
- 2020-08-06 US US16/986,615 patent/US11365244B2/en active Active
-
2021
- 2021-02-26 ZA ZA2021/01318A patent/ZA202101318B/en unknown
-
2022
- 2022-05-18 US US17/747,785 patent/US20230047413A1/en active Pending
- 2022-10-12 JP JP2022164041A patent/JP2022191383A/ja not_active Withdrawn
-
2024
- 2024-03-29 JP JP2024055230A patent/JP2024088689A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111288A1 (es) | Anticuerpos anti-phf-tau y sus usos | |
| CL2020003028A1 (es) | Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos. | |
| ECSP19026178A (es) | Anticuerpos anti-pd-1 y sus usos | |
| DOP2019000165A (es) | Anticuerpos anti-ox40 y sus usos | |
| MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| ECSP18094829A (es) | Anticuerpos anti-cd40 y sus usos | |
| CL2018000829A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| CO2020000214A2 (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
| CO2018000211A2 (es) | Moléculas de anticuerpo que se unen a cd45 | |
| CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
| CO2018003436A2 (es) | Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso | |
| MX2019007554A (es) | Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso. | |
| MX2017012834A (es) | Anticuerpos anti-c1s humanizados y metodos para usarlos. | |
| CO2018010827A2 (es) | Anticuerpos anti-factor bb del complemento y usos de estos | |
| CO2018012497A2 (es) | Anticuerpos de interferón beta y usos de los mismos | |
| DOP2021000229A (es) | Materiales y métodos para modular la inmunidad mediada por cédula t | |
| AR108975A1 (es) | Anticuerpos con baja inmunogenicidad y sus usos | |
| CR20160593A (es) | Anticuerpos antagonistas del interferon alfa y omega | |
| CL2022002766A1 (es) | Anticuerpos anti-phf-pau y sus usos. | |
| CL2021001615A1 (es) | Anticuerpos anti il-36 y procedimientos de uso de estos | |
| MX2020004512A (es) | Anticuerpos anti apolipoproteina c-iii (anti-apoc3) y metodos de uso de los mismos. | |
| UY39699A (es) | Anticuerpos anti-tau y usos de estos | |
| BR112018010596A2 (pt) | anticorpos para cgrp e usos dos mesmos | |
| AR109825A1 (es) | ANTICUERPOS DE INTERFERÓN b Y USOS DE LOS MISMOS |